Search - tctmd.com

Displaying 281 - 300 of 358

Sort: Relevancy | Date

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

News Daily News

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

Jason Kahn

March 06, 2012

News Daily News

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Yael L. Maxwell

March 06, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

Presentation

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

Presenter: C. Von Birgelen

February 20, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Presenter: Emmanouil S. Brilakis, Aristotelis C. Papayannis, Abdul-rahman R. Abdel-karim, Tesfaldet T. Michael, Arif Mahmood, Lorenza B. Makke, Michele Roesle, Donald Haagen, Bavana V. Rangan, Subhash Banerjee

January 03, 2012

Presentation TCT 2012

Microarray Analysis for Nobori Biolimus A9 Eluting Stent and Xience V Everolimus Eluting Stent in Porcine Coronary Artery

Presenter: Arihiro Sumida, Selvamuthu Natarajan, Deepal Panchal, Jinsheng Li, Dongming Hou, Nicholas Chronos, Jaipal Singh, Surendra Chavan

January 03, 2012

Presentation TCT 2012

Healing Responses After Bifurcation Stenting with the Dedicated TRYTON Side-Branch Stent in Combination with XIENCE V Stents: an Angiography and Optical Coherence Tomography Study.

Presenter: Christophe L. Dubois, Tom Adriaenssens, Giovanni Ughi, Mark Coosemans, Bert Ferdinande, Peter Sinnaeve, Walter Desmet

January 03, 2012

Presentation TCT 2012

An All Comers Randomized Trial Comparing Xience Prime and Promus Element Stents. Preliminary Results.

Presenter: Jose M. De la Torre Hernandez, Tamara Garcia Camarero, Piedad Lerena, Dae-Hyun Lee, Fermin Sainz Laso, Virginia Frances Santamaria, Monica Fernandez Menendez, Gonzalo Martin Gorria, Javier Zueco

January 03, 2012

News Industry News

Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent

December 07, 2011

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Industry News

Resolute stent showed positive 1-year results in patients with diabetes

November 09, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

Advertisement

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

SCAAR: Second-Generation DES Improve Hard Outcomes

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Microarray Analysis for Nobori Biolimus A9 Eluting Stent and Xience V Everolimus Eluting Stent in Porcine Coronary Artery

Healing Responses After Bifurcation Stenting with the Dedicated TRYTON Side-Branch Stent in Combination with XIENCE V Stents: an Angiography and Optical Coherence Tomography Study.

An All Comers Randomized Trial Comparing Xience Prime and Promus Element Stents. Preliminary Results.

Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent

Some New-Generation Stents Prone to Longitudinal Distortion

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Resolute stent showed positive 1-year results in patients with diabetes

RAPID GENE: Validation of Point-of-Care Genetic Testing

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content